Eli Lilly has had a mixed few days, posting promising trial results for mid-stage Crohn’s disease drug mirikizumab, undercutting a key insulin from Sanofi in the US, but facing safety conce
European safety regulators have placed restrictions on Pfizer’s Xeljanz, saying it should not be used in the higher dose in some patients with ulcerative colitis because of concerns of incr
Takeda has announced results from its gastro drug Entyvio, showing that it largely outperformed the industry standard – AbbVie’s Humira – in severely active ulcerative colitis.
Ireland’s Cosmo Pharma claimed FDA approval for its traveller’s diarrhoea drug Aemcolo, which some analysts say could be a big threat to a rival drug sold by Bausch Health’s Salix unit.
